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Diabetes is a major health problem for Australia’s Aboriginal and Torres Strait Islander peoples. 
Point-of-care testing for haemoglobin A1c (HbA1c) has been the cornerstone of a long-standing 
program (QAAMS) to manage glycaemic control in Indigenous people with diabetes and 
recently, to diagnose diabetes.  
 
Methods: 
The QAAMS quality management framework includes monthly testing of quality control (QC) 
and external quality assurance (EQA) samples. Key performance indicators of quality include 
imprecision (coefficient of variation [CV%]) and percentage acceptable results. This paper 
reports on the past 15 years of quality testing in QAAMS and examines the performance of 
HbA1c POC testing at the 6.5% cut-off recommended for diagnosis. 
 
Results: 
The total number of HbA1c EQA results submitted from 2002 to 2016 was 29,093. The median 
imprecision for EQA testing by QAAMS device operators averaged 2.81% (SD 0.50; range 2.2 to 
3.9%) from 2002 to 2016 and 2.44% (SD 0.22; range 2.2 to 2.9%) from 2009 to 2016. No 
significant difference was observed between the median imprecision achieved in QAAMS and by 
Australasian laboratories from 2002 to 2016 (p=0.05; two-tailed paired t-test) and from 2009 to 
2016 (p=0.17; two-tailed paired t-test). For QC testing from 2009 to 2016, imprecision averaged 
2.5% and 3.0% for the two levels of QC tested. Percentage acceptable results averaged 90% for 
QA testing from 2002 to 2016 and 96% for QC testing from 2009-2016. The DCA Vantage was 
able to measure a patient and an EQA sample with an HbA1c value close to 6.5% both accurately 



















HbA1c POC testing in QAAMS has remained analytically sound, matched the quality achieved by 





























The prevalence of diabetes in Australia’s Aboriginal and Torres Strait Islander population is 3-4 
times higher than in the non-Indigenous Australian population and the onset of diabetes occurs 
at an earlier age and at much higher rates in Aboriginal and Torres Strait Islander people than in 
the non-Indigenous population [1].  Aboriginal and Torres Strait Islander people also experience 
four-times more deaths due to diabetes than non-Indigenous Australians [1].  
 
The early detection and management of diabetes through good glycaemic control is crucial in 
preventing long-term micro- and macro-vascular complications of diabetes including end-stage 
renal disease, retinopathy, neuropathy and cardiovascular disease. 
 
Point-of-care (POC) pathology testing allows pathology tests to be conveniently conducted 
during a patient consultation with results rapidly available for timely clinical action. POC testing 
for haemoglobin A1c (HbA1c) and urine albumin:creatinine ratio (ACR) on the DCA 2000/Vantage 
device (Siemens HealthCare Pty Ltd) has been the cornerstone of the QAAMS (Quality Assurance 
for Aboriginal and Torres Strait Islander Medical Services) POC Testing Program for diabetes 
management in Australia for the past 18 years. The QAAMS Program commenced as a small pilot 
in 1999. Through continuing funding from the Australian Government, the program has grown to 
include just over 200 DCA devices at Indigenous health services across Australia, the majority of 
which (greater than 75%) are in rural and remote locations. The program empowers Aboriginal 
Health Workers (Aboriginal people who are qualified in the practice of primary healthcare and 
who live and work in the community) to conduct POC testing on their Indigenous patients with 
diabetes when the patients visit the health service, with the patients receiving immediate clinical 
follow-up on their POC results during that same visit. POC testing has been shown to be 
culturally safe and clinically effective in supporting diabetes care for Australia’s Indigenous 

















Point-of-Care Testing, on behalf of the Australian Government, with the Royal College of 
Pathologists of Australasia (RCPA) Quality Assurance Programs Pty Ltd providing the proficiency 
testing component of the program.  
 
The fundamental elements that have been responsible for the longevity and sustainability of 
QAAMS are comprehensive training and competency assessment programs, continuous 
surveillance of analytical quality through quality control (QC) and external proficiency (QA) 
testing, and intensive scientific and technical support services for participating services [7-9]. 
 
Haemoglobin A1c (HbA1c) has been a well-established pathology marker for monitoring long 
term diabetes control for more than 30 years. In Australia, since 2014, the HbA1c test has been 
approved to diagnose diabetes in accredited laboratories. This paper reviews the quality 
management framework employed by QAAMS, reports on the analytical performance of the 
HbA1c test on DCA devices enrolled in the program over the last 15 years (2002-2016) and 
examines the performance of the DCA Vantage POC testing device at the 6.5% (48 mmol/mol) 
cut-off value used in Australia for HbA1c for the diagnosis of diabetes [10]. 
 
2. Methods 
The quality management framework for QAAMS comprises training for device operators, 
competency certification, continuous testing of quality control (QC) and external quality 
assurance (QA) samples and support for participating services. 
 
2.1. Point-of-Care Testing Device 
Over the lifetime of QAAMS, two models of the Siemens DCA point-of-care testing device have 
been used in the program. From 1999 to mid-2009, HbA1c testing was conducted on the DCA 

















newer model of the device, the DCA Vantage. Analytically, the two models are identical, with 
both measuring HbA1c by a light-scattering, latex inhibition agglutination immunoassay [11]. The 
DCA Vantage provides a larger results display screen, greater functionality for data entry and has 
capacity for electronic transfer of results. 
 
2.2. Training of device operators 
Device operators in QAAMS have access to a wide range of training resources, including a hard 
copy training manual, colour posters providing simple step-by-step guides showing how to 
conduct patient, QC and QA tests; a training power-point presentation; web-streamed videos of 
training available 24 hours a day/7 days a week on the QAAMS website (www.qaams.org.au); 
and a DVD containing all the above resources in electronic form. Training for participants is 
available in flexible formats including face-to-face (on-site visits, regional or annual workshops) 
or e-learning options (teleconference, videoconference or on-line videos). At the completion of 
training, all operators undergo a written and practical assessment to obtain a competency 
certificate (with 2-year expiry) as a qualified POCT device operator in the program. 
 
2.3. Proficiency Testing 
QAAMS participants are sent their proficiency testing (external quality assurance testing [EQA]) 
kits at the start of each calendar year. Each kit contains 24 lyophilised samples with 
reconstitution fluid; the samples comprise 6 paired and linearly related levels of HbA1c covering 
a range from approximately 5 to 12%. Each sample has an assigned target value and limits for 
acceptable performance which currently, for HbA1c, are +0.4 up to 6.7% and 6% at 
concentrations greater than 6.7% [12]. Two samples are made up and tested each month and 


















The material provided is the same as that used in the RCPA QAP’s Glycohaemoglobin Program 
for Australasian laboratories, which enables direct comparison of analytical performance across 
the two programs.  
 
At the start of each month, each service receives a monthly summary report detailing 
performance for QAP testing during the previous month. The report format has undergone 
modification and refinement over the years, with a focus to improve user-friendliness and 
cultural safety while providing relevant, readily interpretable tabular and graphical information 
on analytical performance. The report includes: a list of results submitted for each sample tested 
(colour coded green, orange or red, depending on their quality), the ‘target values’ for those 
samples (the median value of all results received) and a histogram showing the (de-identified) 
results returned for each sample by all participants, with an arrowhead pointing to the results 
reported by the individual service concerned. This report enables a simple and immediate visual 
assessment of performance.  
 
At the completion of each 6-monthly cycle, key performance indicators of quality are calculated 
including: 
 Percentage acceptable results (the percentage of results within the pre-set allowable 
limits of performance set by the RCPA QAP, as reported above); this indicator provides a 
measure of the accuracy of EQA testing, and,  
 The median within-site imprecision (CV%); this indicator used as a standard measure of 
imprecision across all laboratory proficiency testing programs run by the RCPA QAP, as 
well as QAAMS. 

















In QAAMS, device operators at all participating services are required to test samples with two 
levels of HbA1c, reflective of a patient with optimal [approximately 5.5%] and poorly controlled 
diabetes [around 11.0%], from the Siemens Normal and Abnormal HbA1c QC kit each month.  
 
From 1999 to 2015, device operators recorded their monthly QC results manually on a colour-
coded QC result sheet and faxed them to the QAAMS Quality Manager from the International 
Centre for Point-of-Care Testing. The QC results sheets were designed to provide operators with 
a guide to immediately interpret the quality of their QC result and the action to be taken. The 
colour codes mimicked a ‘traffic light’ system. A QC result which fell within the ‘green’ zone 
meant the result was of sound quality and patient testing could proceed at the service; a result 
which fell within the ‘orange zone’ meant that patient testing could still proceed but the quality 
of testing would be monitored closely over subsequent months by the QAAMS Quality Manager. 
A ‘red’ result meant that the QC test result should be rejected and patient testing should cease 
until the reason for unacceptable performance had been addressed and resolved by the QAAMS 
Quality Manager.  
 
Since 2016, QC testing results from each service can be entered electronically in a newly-
developed ‘QC Results’ section on the QAAMS website, with entered results displayed using the 
same colour-coded system as described above and results being available for immediate review 
by the QAAMS Quality Manager.  
 
The acceptable limits for QC testing are: within ±7.5% from the target value (set by the 
manufacturer for each lot number of QC kit) for the ‘green zone’, between ±7.5% and 10% from 
the target value for the ‘orange zone’ and >10% for the ‘red zone’. QC limits were designed to 
provide a crude guide to overall analytical performance at the health service level and allowed 

















participant results. The QC limits equate to between-site goals for total allowable error; that is, 
they encompassed allowable error due to both inaccuracy and imprecision.  At six-monthly 
intervals (corresponding to the EQA testing cycles), the within-service imprecision (CV%) for QC  
testing is calculated for each individual service, following the receipt of a minimum of four QC 
results for each level tested. The median within-site imprecision is then calculated and, like EQA 
testing, can be compared with the analytical goals set by the program. 
 
2.5. Support Services 
As part of its quality management package, QAAMS provides a telephone support hotline, 
manned by a QAAMS scientist during normal business hours from Monday to Friday.  
 
2.6. Performance of DCA Vantage at Diagnosis Cut-Off (HbA1c 6.5%) 
The analytical performance of the DCA Vantage specifically at an HbA1c of 6.5% (the cut-off 
value used for the diagnosis of diabetes in Australia) was examined in two ways. 
 
Firstly, within-day (n=10) and between-day (n=10) imprecision studies were performed by a 
Centre staff member with limited training, on three different DCA Vantage devices, using a de-
identified patient whole blood sample with an HbA1c value of 6.5%, as measured by an HPLC 
method (BioRad Variant II) in the local accredited pathology laboratory. 
 
Secondly, one of the six (paired) samples supplied by the RCPA Quality Assurance Programs Pty 
Ltd by QAAMS has a target value for HbA1c of 6.8% (close to the cut-off value of 6.5%). The 
median within-site imprecision achieved by QAAMS participants for this specific EQA sample was 
calculated from all results returned for each QA testing cycle for the past 5 years (cycles 26-35, 


















Throughout the results section the data has been analysed from (i) 2002 to 2016, incorporating 
data from both the superseded DCA 2000 and the DCA Vantage and (ii) from 2009 to 2016 when 
the DCA Vantage was introduced into the program. 
 
3.1. Number of POCT Devices and Quality Assurance Tests for HbA1c 
Across the lifetime of the QAAMS Program, the number of POCT devices (DCA 2000 and/or DCA 
Vantages) at participating services has risen steadily from 45 in 1999 to 200 in 2016 (Fig. 1). The 
total number of external quality assurance samples for HbA1c tested in the 30 testing cycles 
from 2002 to 2016 was 29,093. 
  
3.2. Percentage Acceptable Results 
The percentage of HbA1c results for QA testing that were within the allowable limits of 
performance set by the program organisers (see above) averaged 89.5% (SD 5.5; range 77-96%) 
from 2002-2016 and 94.0% (SD 1.3; range 92-96%) from 2009 to 2016 when the DCA Vantage 
became available in the program.  
 
For QC testing, the percentage of acceptable HbA1c results for QC testing averaged 95.6% (SD 
2.61; range 88-98%) over the 16 testing cycles from 2009 to 2016. 
 
3.3 Imprecision 
Fig. 2 displays the median within-site imprecision (CV%) for HbA1c QA testing achieved by 
participating services in the program over the past 15 years from 2002 to 2016.  The median 
imprecision achieved nationally by QAAMS device operators has averaged 2.81% (SD 0.50; range 
2.2 to 3.9%) from 2002 to 2016 and 2.44% (SD 0.22; range 2.2 to 2.9%) from 2009 to 2016 since 


















It is possible to directly compare the performance of QAAMS services with Australian 
laboratories because the QAAMS and laboratory-based RCPA Glycohaemoglobin QAP use the 
same material for HbA1c testing. The median imprecision achieved by Australasian laboratories 
was 2.69% (SD 0.42; range 2.1 to 3.6%) from 2002 to 2016 and 2.34% (SD 0.16; range 2.1 to 
2.6%) from 2009-2016. There was no statistically significant difference the median imprecision 
achieved by QAAMS and by Australasian laboratories from 2002 to 2016 (p=0.05; two-tailed 
paired t-test) and from 2009 to 2016 (p=0.17; two-tailed paired t-test).  
 
From 2002 to 2008, the Australian Government recommended that HbA1c POC testing in 
QAAMS should achieve a minimum imprecision (CV%) goal of 4% or less. Since 2009, the 
Government, consistent with international recommendations, have recommended that the 
desirable analytical goal for imprecision for HbA1c testing in QAAMS should be ≤3% [13-16]. 
Results from more than 29,000 QA samples tested in QAAMS has shown that HbA1c POC testing 
has consistently been equivalent to laboratory testing for HbA1c and met these analytical goals 
over the past decade and a half. 
 
Table 1 summarises the median within-site imprecision for HbA1c QC testing from 2009-2016 
when the DCA Vantage replaced the DCA 2000. For the ‘Normal’ QC level, the imprecision has 
averaged 2.5% (SD 0.46; range 1.8% to 4.0%). For the ‘Abnormal’ QC level, imprecision has 
averaged 3.0% (SD 0.43; range 2.3% to 3.8%) across this time period. 
 
3.4 Performance of DCA Vantage at Diagnosis Cut-Off (HbA1c 6.5%) 
The imprecision observed for HbA1c POC testing when a patient sample with a laboratory-
assigned value of 6.5% was measured using three different DCA Vantage devices is summarised 

















devices was 6.58%, with inter-device CV%s ranging from 1.4 to 1.8%. For the between-day study, 
the mean HbA1c value across the three devices was 6.54%, with CV%s ranging from 1.7 to 2.2%. 
For the EQA sample that had a target value of 6.8%, the program-wide imprecision achieved by 
the DCA Vantage devices in QAAMS for this level of HbA1c over the past 5 years (and 10 testing 




Haemoglobin A1c (HbA1c) has been a well-established pathology marker for long-term diabetes 
control for more than 30 years, with HbA1c providing a weighted estimate of a patient’s 
glycaemic control over the preceding three- to four-month window. HbA1c is measured serially 
on patients with diabetes to track their glycaemic control across time and, importantly, the test 
needs to distinguish clinically significant changes in a patient’s glycaemic control over time; for 
these reasons, it is critical that the test method for HbA1c is precise. As mentioned previously, 
within Australia, there is general consensus that  a CV% of ≤2% is the optimal analytical goal for 
HbA1c, with ≤3% being the desired goal and ≤4% being the minimum goal for HbA1c devices (no 
matter whether the device is used in the laboratory or at the point of care)[16]. In the QAAMS 
Program, results from EQA testing in particular show the imprecision for HbA1c POC testing has 
continued to improve across the past 15 years and has met the profession-based analytical goals. 
In addition, there has been no statistically significant difference between the imprecision 
achieved by QAAMS and Australian laboratories over this period. 
 
In recent times, there has been considerable debate in the international literature about the 
potential to use HbA1c for the diagnosis of diabetes [17-23], with the 6.5% cut-off representing 
the level at which the prevalence of moderate retinopathy begins to increase exponentially [24]. 

















accredited pathology laboratories in late 2014 (along with a Medicare rebate item number). The 
decision followed published recommendations on analytical performance criteria required for 
the use of HbA1c as a diagnostic tool [25]; these recommendations stated that a test method 
using HbA1c for diagnosis ‘could be relied on, in the context of using HbA1c as a diagnostic tool, 
if the routine coefficient of variation [imprecision of the test] is ≤3% … and external quality 
assurance results are consistently within … allowable limits of performance’.  
 
For POC testing devices used outside the laboratory, the use of the HbA1c test for diagnosis has 
been even more contentious. There are a large number (more than 15) of POC HbA1c testing 
devices that are available on the global market and each has different analytical performance 
characteristics [10]. This led the American Diabetes Association (ADA) to hold the view from 
2009 to 2011 that:  ‘The ADA cautions that point-of-care devices for measuring HbA1c should not 
be used for diagnosis’ [26] and ‘Point-of-care instruments have not yet been shown to be 
sufficiently accurate or precise for diagnosing diabetes’ [17]. The 2017 ADA recommendations 
state that: ‘Although point-of-care A1C assays may be NGSP certified, proficiency testing is not 
mandated for performing the test, so use of point-of-care testing assays for diagnostic purposes 
is not recommended but may be considered in the future, if proficiency testing is performed and 
documented’ [27]. There is strong evidence from international studies that there are POCT 
devices available that perform to analytically acceptable standards in terms of accuracy and 
precision at the diagnosis cut-off point (and indeed across all levels of HbA1c seen in patients 
with diabetes) [28-30]. We argue that these POCT devices are suitable for the diagnosis of 
diabetes and the performance of each individual POC device should be assessed independently 
when considering its suitability for use to diagnose diabetes. Sneenan et al [31] also support the 


















In December 2015, the Australian Government approved the use of the HbA1c test for diagnosis 
in Indigenous primary care services enrolled exclusively in the QAAMS POC Testing Program, 
along with a separate Medicare item number. This landmark decision was based largely on the 
consistently high analytical quality of POC testing for HbA1c in QAAMS, as evidenced by the 
results of continuing EQA and QC testing over the past 15 years.   
 
In summary, the QAAMS Program sets an international benchmark for POC testing models for 
diabetes management. The program has demonstrated longevity and been shown to be 
clinically, culturally and operationally effective. Underpinning its sustainability is the 
commitment to continuing surveillance of the analytical quality of POC testing.   
 
Acknowledgements 
The QAAMS Program been continuously funded by the Australian Government Department of 
Health since 1999.  
 
The Flinders University International Centre for Point-of-Care Testing receives research support 



















[1] D Atkinson, R Murray, S Couzos, Diabetes, in: S Couzos and R Murray (Eds.), Aboriginal 
Primary Health Care. An Evidence-based Approach 3rd edn. Oxford University Press, South 
Melbourne, Victoria, 2008, pp. 521-574. 
 
[2] M.D. Shephard, Cultural and clinical effectiveness of the 'QAAMS' point-of-care testing model 
for diabetes management in Australian Aboriginal medical services, Clin. Biochem. Rev. 27 (2006) 
161‒170.  
 
[3] M. Shephard, C. O'Brien, A. Burgoyne, J. Croft, T. Garlett, K. Barancek, H. Halls, B. McAteer, L. 
Motta and A. Shephard, A Review of the Cultural Safety of a National Indigenous Point-of-Care 
Testing Program for Diabetes Management, Aust. J. Prim. Health. 22 (2016) 368-
374.http://dx.doi.org/10.1071/PY15050  
 
[4] B.A. Spaeth, M.D.S. Shephard, S. Schatz, Point-of-care testing for haemoglobin A1c in remote 
Australian Indigenous communities improves timeliness of diabetes care. Rural Remote Health. 
14 (2014) 2849. (Online). http://www.rrh.org.au/articles/printviewnew.asp?ArticleID=2849   
 
[5] M.D.S. Shephard, J. Gill, The national QAAMS Program – A practical example of PoCT working 
in the community. Clin. Biochem. Rev. 31 (2010) 95-99.  
Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2924122/       
 
[6] M.D.S. Shephard, L. Causer, R. Guy, Point-of-care testing in rural, remote and Indigenous 
settings, in: M. Shephard (Ed.), A Practical Guide to Global Point-of-Care Testing, CSIRO 
Publishing., Melbourne, Australia, 2016, pp. 343-354. 
 
[7] M. Shephard, B. Spaeth, L. Motta, A. Shephard, Point-of-care testing in Australia: Practical 
advantages and benefits of community resiliency for improving outcomes, in:  G. Kost, C. Curtis 
(Eds.), Global Point-of-Care: Strategies for Disasters, Complex Emergencies, and Public Health 
Resilience, AACC Press., Washington DC, pp. 527‒535.  
 
[8] M.D.S. Shephard, J.P. Gill, The analytical quality of point-of-care testing in the ‘QAAMS’ model 
for diabetes management in Australian Aboriginal medical services. Clin. Biochem. Rev. 27 (2006) 
185-190. 
 
[9] M.D.S. Shephard, J.P. Gill, An innovative Australian point-of-care model for urine 
albumin:creatinine ratio testing that supports diabetes management in indigenous medical 
services and has international application, Ann. Clin.  Biochem. 42 (2005) 208-215. 
 
[10] M. Shephard, J. Shaw, P. Zimmet, Point-of-care testing for diabetes: haemoglobin A1c, in: M. 
Shephard (Ed.), A Practical Guide to Global Point-of-Care Testing, CSIRO Publishing., Melbourne, 
Australia, 2016,  pp. 119-132. 
 
[11] A. St John, T.M.E. Davis, I. Goodall, M.A. Townsend, C.P. Price, Nurse-based evaluation of 
point-of-care assays for glycated haemoglobin, Clin. Chim. Acta. 365 (2006) 257‒263. 
 
[12] RCPA QAP, 2015-2016 Allowable limits of performance. Royal Australasian College of 


















[13] M.D.S. Shephard, Analytical goals for point-of-care testing used for diabetes management in 
Australian health care settings outside the laboratory. Point Care. 5 (2006) 177‒185. 
 
[14] M. Shephard, A. Shephard, L. Watkinson. B. Mazzachi, P. Worley, Design, implementation 
and results of the Quality Control program for the Australian Government’s Point of Care Testing 
in General Practice Trial. Ann. Clin. Biochem. 46 (2009) 413–419. 
 
[15] I. Goodall, P. Colman, H. Schneider, M. McLean, G. Barker, (2007) Desirable performance 
standards for HbA1c analysis - precision, accuracy and standardisation. Clin. Chem. Lab. Med. 45 
(2007) 1083‒1097.  
 
 [16] M. Shephard, J. Shaw J, P. Zimmet, Point-of-care testing for diabetes: haemoglobin A1c, in: 
M. Shephard (Ed.), A Practical Guide to Global Point-of-Care Testing, CSIRO Publishing., 
Melbourne, Australia, 2016, pp. 119-132. 
 
[17] International Expert Committee, International expert committee report on the role of the 
A1C assay in the diagnosis of Diabetes, Diabetes Care. 32 (2009) 1327‒1334. 
 
[18] World Health Organisation, Use of glycated haemoglobin (HbA1c) in the diagnosis of 
diabetes mellitus, Diabetes Res. Clin. Pract. 93 (2011) 299‒309. 
 
[19] W. John and the UK Department of Health Advisory Committee on Diabetes, Expert Position 
Statement: Use of HbA1c in the diagnosis of diabetes mellitus in the UK. The implementation of 
World Health Organization guidance 2011, Diabet. Med. 29 (2012) 1350‒1357. 
 
[20] New Zealand Society for the Study of Diabetes, New role of HbA1c in diagnosing type 2 
diabetes, BPJ. 42 (2012) 14‒19. 
 
[21] IDF Guideline Development Group, Global guideline for type 2 diabetes, Diabetes Res. Clin. 
Pract. 104 (2014) 1‒52. 
 
[22] American Diabetes Association, Standards of medical care in diabetes – 2015, Diabetes Care. 
38 (2015) Supplement 1, S1‒S93. 
 
[23] M. d'Emden, J. Shaw,  P. Colman, C. Colagiuri, S. Twigg, G. Jones, I. Goodall, H. Schneider,  N. 
Cheung, The role of HbA1c in the diagnosis of diabetes mellitus in Australia, Med. J. Aust. 197 
(2012) 1‒3. 
 
 [24] S. Colagiuri, C. Lee, T. Wong, B. Balkau, J. Shaw, K. Borch-Johnsen, Glycemic thresholds for 
diabetes-specific retinopathy: implications for diagnostic criteria for diabetes, Diabetes Care. 34 
(2011) 145‒150. 
 
[25] J. Shaw, M. d'Emden, I. Goodall, Is Australia ready to use glycated haemoglobin for the 
diagnosis of diabetes? Med. J. Aust. 195 (2011) 7‒8. 
 
[26] D.B. Sacks, M. Arnold, G.L. Bakris, D.E. Bruns, A.R. Horvath, M.S. Kirkman, A. Lernmark, B.E. 
Metzger, D.M. Nathan, Guidelines and recommendations for laboratory analysis in the diagnosis 
and management of diabetes mellitus, Clin. Chem. 57 (2011) e1‒e47. 
 
[27] American Diabetes Association. Standards of Medical Care in Diabetes, Diabetes Care.  40 


















[28] E. Lenters-Westra, R.J. Slingerland, Six of eight haemoglobin A1c Point-of-Care Instruments 
do not meet the general accepted analytical performance criteria, Clin. Chem.  56 (2010) 44‒52.  
 
[29] E. Lenters-Westra, R.J. Slingerland, Three of 7 hemoglobin A1c point-of-care instruments do 
not meet generally accepted analytical performance criteria, Clin. Chem. 60 (2014) 1062‒1072. 
 
[30] NHS Purchasing and Supply Agency. Centre for Evidence-based Purchasing, Buyer’s guide 
Blood glucose systems CEP 08008. London, UK, 2008, 
http://www.clinbiochem.info/buyersguideglucose2008.pdf . 
 
[31] Sreenan S, Tormey W,  American Diabetes association recommendations on haemoglobin 











































Fig.2. Median within-site imprecision (CV%) achieved by participating QAAMS services for HbA1c 


















Table 1  
Median within-site imprecision (CV%) achieved for HbA1c QC testing from 2009-2016. 
 
Year 2009  2010  2011  2012  2013  2014  2015  2016  
Cycle 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 
QC 
Normal 2.2 1.8 2.5 2.6 4.0 2.3 2.9 2.8 2.4 2.6 2.1 2.8 2.3 2.4 2.4 2.5 
QC 
Abnormal 


















Table 2  
Within- and between-day imprecision for HbA1c using a patient sample with a laboratory reference 
value of 6.5%. 
 
  
DCA Vantage 1 DCA Vantage 2 DCA Vantage 3 
Within-day imprecision  
   
Mean HbA1c (%) 6.61 6.60 6.52% 
SD  0.09 0.12 0.11 
CV% 1.36% 1.82% 1.69% 
Number of repeats 10 10 10 
    
Between-day imprecision    
Mean HbA1c (%) 6.60 6.51 6.52 
SD  0.12 0.11 0.14 
CV% 1.82% 1.69% 2.15% 


































Program-wide imprecision achieved by the DCA Vantages in QAAMS for the external quality assurance 
sample with an HbA1c value of approximately 6.8%  over the 5 year period from 2012  to 2016. 
 
Year 2012 2013 2014 2015 2016 
Cycles 26,27 28,29 30,31 32,33 34,35 
QAAMS  
     
Mean HbA1c (%) 6.92 7.01 6.76 7.04 6.82 
SD 0.19 0.20 0.19 0.20 0.17 
CV% 2.75% 2.85% 2.81% 2.84% 2.49% 
Number 284 332 460 489 482 
Laboratory 
     



















 From 2002 – 2016 29,093 HbA1c external quality assurance samples submitted by 
QAAMS  
 Matched the quality achieved by Australasian laboratories and met analytical goals  
 Quality performance goals met when HbA1c POC testing for diagnosis introduced 
 QAAMS HbA1c point-of-care testing has been analytically sound for the last 15 years 
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